Gossamer Bio (GOSS) Stock Forecast, Price Target & Predictions
GOSS Stock Forecast
Gossamer Bio stock forecast is as follows: an average price target of $3.75 (represents a 346.43% upside from GOSS’s last price of $0.84) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
GOSS Price Target
GOSS Analyst Ratings
Buy
Gossamer Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 08, 2022 | H.C. Wainwright | $5.00 | $2.16 | 131.48% | 495.24% | |
Dec 07, 2022 | Barclays | $2.00 | $2.36 | -15.25% | 138.10% | |
Dec 07, 2022 | Raymond James | $5.00 | $2.36 | 111.86% | 495.24% | |
Dec 06, 2022 | David Hoang | SMBC Nikko | $3.00 | $2.36 | 27.12% | 257.14% |
Apr 26, 2022 | Barclays | $12.00 | $8.45 | 42.01% | 1328.57% | |
Apr 26, 2022 | Raymond James | $10.00 | $9.08 | 10.13% | 1090.48% |
Gossamer Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.84 | $0.84 | $0.84 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jun 24, 2024 | Oppenheimer | Buy | Outperform | Initialise |
May 06, 2024 | Guggenheim | Positive | Initialise | |
May 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Mar 06, 2024 | Goldman Sachs | Buy | Buy | Hold |
Mar 07, 2023 | Raymond James | Outperform | Market Perform | Downgrade |
Dec 08, 2022 | Oppenheimer | Buy | Buy | Hold |
Dec 07, 2022 | Goldman Sachs | Buy | Buy | Hold |
Dec 07, 2022 | UBS | Buy | Buy | Hold |
Dec 07, 2022 | Barclays | Overweight | Equal-Weight | Downgrade |
Dec 07, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Dec 06, 2022 | SMBC Nikko | Neutral | Downgrade | |
Nov 17, 2022 | Raymond James | Outperform | Outperform | Hold |
Apr 26, 2022 | Barclays | Overweight | Overweight | Hold |
Apr 26, 2022 | Zacks Investment Research | Hold | Upgrade | |
Apr 26, 2022 | Citigroup | Outperform | Upgrade |
Gossamer Bio Financial Forecast
Gossamer Bio Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $23.71M | $10.00M | $9.48M | $9.48M | $10.47M | $3.56M | $3.56M | $3.56M | $6.83M | $8.53M | $114.29M |
High Forecast | $23.71M | $10.00M | $9.48M | $9.48M | $10.47M | $3.56M | $3.56M | $3.56M | $17.70M | $8.53M | $114.29M |
Low Forecast | $23.71M | $10.00M | $9.48M | $9.48M | $10.47M | $3.56M | $3.56M | $3.56M | $924.02K | $8.53M | $114.29M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Gossamer Bio EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Gossamer Bio Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-21.39M | $-31.59M | $-39.52M | $-39.54M | $-35.08M | $-44.36M | $-43.01M | $-43.01M | $-38.48M | $-33.31M | $114.68M |
High Forecast | $-21.39M | $-31.59M | $-39.52M | $-39.54M | $-35.08M | $-44.36M | $-43.01M | $-33.95M | $-18.11M | $-33.31M | $114.72M |
Low Forecast | $-21.39M | $-31.59M | $-39.52M | $-39.54M | $-35.08M | $-44.36M | $-43.01M | $-49.80M | $-47.53M | $-33.31M | $114.64M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Gossamer Bio SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Gossamer Bio EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | 3 |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.09 | $-0.14 | $-0.17 | $-0.17 | $-0.15 | $-0.20 | $-0.19 | $-0.19 | $-0.17 | $-0.15 | $0.51 |
High Forecast | $-0.09 | $-0.14 | $-0.17 | $-0.17 | $-0.15 | $-0.20 | $-0.19 | $-0.15 | $-0.08 | $-0.15 | $0.51 |
Low Forecast | $-0.09 | $-0.14 | $-0.17 | $-0.17 | $-0.15 | $-0.20 | $-0.19 | $-0.22 | $-0.21 | $-0.15 | $0.51 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Gossamer Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
FDMT | 4D Molecular Therapeutics | $6.32 | $38.33 | 506.49% | Buy |
INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
BMEA | Biomea Fusion | $4.64 | $23.33 | 402.80% | Buy |
XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
GOSS | Gossamer Bio | $0.87 | $3.75 | 331.03% | Buy |
ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |